HER2-Low Treatment – The Future of this Important Biomarker
Paolo Tarantino, from the Dana-Farber Cancer Institute, highlights the transformative potential of novel antibody-drug conjugates in treating HER2-positive and HER2-low breast cancer. Through recent trials, Tarantino challenges traditional assumptions about HER2 expression and demonstrates promising outcomes for HER2-low tumours.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen